<原著>膠原病に対するLevamisoleの効果に関する実験的ならびに臨床的観察

概要

論文の詳細を見る
Levamisole (LMS), known as an anthelminthic agent with immunostimulatory actions, was used in the treatment of the New Zealand black and New Zealand white F_1 hybrid (B/W) mice, which are known to spontaneously develop a disease similar to human systemic lupus erythematosus (SLE). Large dose group (20 mg/kg once weekly from three months of age) was protected against the development of anti-n-DNA antibody, proteinuria and lupus nephritis, but did not prevent the development of antibodies to nuclear antigen (ANA). ANA was observed rather earlier and more prominently than control group. The discrepancy between ANA and anti-n-DNA antibody is not known. It may be due to the antibodies of other nuclear components, such as extractable nuclear antigen. LMS was medicated to the seven cases of mild or non-acute phase human SLE. The skin eruption, proteinuria, epileptic attack or involuntary movement of the limbs were disappeared in some cases. ANA titer was not elevated in all cases. The histologic findings of bioptic kidneys at six months after the administration of LMS included slight improvement of the lupus nephritis. Twelve cases of rheumatoid arthritis were also treated with LMS. After three or six months' treatment, significant improvement was recorded in morning stiffness, arthralgia, RAHA titer, erythrocyte sedimentation rate and CRP except four cases in which the treatment with LMS was interrupted because of side effects.
近畿大学の論文
1979-09-25

<原著>膠原病に対するLevamisoleの効果に関する実験的ならびに臨床的観察

スポンサーリンク

概要

著者

関連論文

スポンサーリンク